Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks

Moomoo NewsNov 14 01:30 ET

WuXi Biologics Germany to Enhance Capabilities With New Prefilled Syringes Line

PR NewswireNov 13 23:00 ET

[Brokerage Focus] China Merchants maintains a "shareholding" rating for Wuxi Bio (02269), pointing to the expansion of the animal health biopharmaceutical field, which is expected to bring incremental performance.

Jingu Finance | China Merchants Securities issued a research report stating that wuxi bio (02269) announced the launch of PawBio animal health biopharmaceutical one-stop solution in early November. The firm believes that as a leading player in the human biopharmaceutical CDMO industry, with rich project experience, leading service quality, high customer recognition, expanding its business to the animal biopharmaceutical field could bring new business growth opportunities for the company. The firm also mentioned that with changes in family structures, pets have become increasingly important emotional support and daily companions for more and more people. Mars Inc. recently released the largest global pet survey report in terms of coverage and sample data.

Golden Guard Financial NewsNov 12 01:54 ET

Trump Government Likely to Still Pass Biosecure Act -- Market Talk

WSJNov 6 23:01 ET

Hong Kong stocks are active | CRO concepts generally rise, medical insurance negotiations support innovative drugs, and under the environment of interest rate cuts, global biomedical financing will rebound.

The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories (06821) rose by 4.95%, to HKD 59.4; Tigermed (03347) rose by 4.94%, to HKD 38.25; Wuxi Apptec (02359) rose by 3.88%, to HKD 53.5.

Zhitong FinanceNov 5 01:34 ET

Wuxi bio launches the technology platform WuXia RidGS, empowering customers to develop non-antibiotic cell lines.

Shanghai, October 28, 2024 / PRNewswire / -- China's leading contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics (2269.HK) announces the launch of the WuXia RidGS cell line construction platform based on high-yield glutamine synthetase (GS) in Chinese hamster ovary (CHO) expression system. The platform serves as a non-antibiotic cell line development tool, utilizing zinc finger nuclease (ZFN) technology to knock out the endogenous GS gene in CHO cells. WuXia RidGS is derived from

PR NewswireOct 28 05:00 ET